2
1
Cat. No. | Product Name | ||
---|---|---|---|
L3400 | 临床期小分子药物库 | 3404 compounds | |
3404 个临床期化合物集合,可用于高通量筛选和高内涵筛选; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5519 |
Bivalirudin
BG-8967,比伐卢定,Hirulog-1 |
Thrombin | Proteases/Proteasome |
Bivalirudin (BG-8967) 是一种直接凝血酶(thrombin)抑制剂,是一种肽类抗凝剂,可在侵入性心脏病,特别是在经皮冠状动脉介入中用于抗凝。 | |||
T84595 |
2,3-dinor Prostaglandin E1
2,3-dinor PGE1 |
Others | Others |
Prostaglandin E1 (PGE1), though not predominantly found in nature, plays a significant role in clinical treatments, addressing conditions such as peripheral occlusive vascular disease, erectile dysfunction, and neonatal cardiology issues. The metabolism of PGE1 primarily begins with the oxidation at C-15, producing 13,14-dihydro-15-keto PGE1 as its major metabolite. Alternatively, inhibiting this pathway or overwhelming it with too much PGE1 could potentially enhance the production of 2,3-dinor ... |